NCT01211236

Brief Summary

The main objective of the trial was to study the efficacy of bagged larvae on wound debridement in comparison to classical treatments. The secondary outcome was to assess wound healing, treatment related pain, microbiological modifications, adverse events, comfort of the dressing and duration of wound care. We performed a randomized, double-blind, multicenter, controlled, prospective phase III trial in three referral institutional centers of hospitalized care in Caen, Lisieux and Lyon, France. A total of 120 patients with a non-healing fibrinous wound ≤ 40cm2, less than 2cm-deep, and an ankle-brachial pressure index (ABPI) ≥ 0.8 were included, from March 2005 to December 2008. During two weeks´ hospitalization, patients received either Maggot Debridement Therapy (MDT, changes of bagged larvae twice a week) or classical treatments (mechanical debridement and classical dressings performed three times a week). At discharge, classical dressings were applied and a follow-up visit performed at D30. Main outcome measure was the comparison of the reduction of fibrin percentage on wounds treated with MDT and classical treatments at D15. The percentages of fibrin were measured using a computerized planimetry software package, Canvas (ACD Systems, British Columbia, Canada), which enables the quantification of color surface variations in a wound after manual delimitation (using a mouse) on a series of photographic images.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P25-P50 for phase_3

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2006

Completed
4.7 years until next milestone

First Submitted

Initial submission to the registry

September 28, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 29, 2010

Completed
Last Updated

September 29, 2010

Status Verified

September 1, 2010

First QC Date

September 28, 2010

Last Update Submit

September 28, 2010

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percent of Fibrin changes from day 0 to day 15

Secondary Outcomes (1)

  • Percent of healing changes from day 0 to day 15

Study Arms (2)

Maggot Debridement Therapy

EXPERIMENTAL
Other: application of wound dressing made of bio-bags (vitapads) containing maggots

control

ACTIVE COMPARATOR
Other: application of classical hydrogel/alginate wound dressing

Interventions

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patient between 18 and 90 years old
  • patients with a non-healing fibrinous wound ≤ 40cm2 (pressure ulcer or venous ulcers
  • pressure ulcers were less than 2cm-deep
  • limb wounds were venous ulcers with an ankle-brachial pressure (ABP)≥ 0.8
  • signed informed consent

You may not qualify if:

  • patients pregnant or lactating
  • patients with neuropathy
  • patients perforant ulcer of the foot
  • patients with dementia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Hospital of Caen, dermatology department

Caen, Calvados, 14000, France

Location

Robert Bisson Hospital

Lisieux, Calvados, 14107, France

Location

Hopital des armées Desgenettes

Lyon, Rhone, 69000, France

Location

Related Publications (1)

  • Opletalova K, Blaizot X, Mourgeon B, Chene Y, Creveuil C, Combemale P, Laplaud AL, Sohyer-Lebreuilly I, Dompmartin A. Maggot therapy for wound debridement: a randomized multicenter trial. Arch Dermatol. 2012 Apr;148(4):432-8. doi: 10.1001/archdermatol.2011.1895. Epub 2011 Dec 19.

MeSH Terms

Conditions

Pressure Ulcer

Condition Hierarchy (Ancestors)

Skin UlcerSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 28, 2010

First Posted

September 29, 2010

Study Start

February 1, 2006

Last Updated

September 29, 2010

Record last verified: 2010-09

Locations